Home » BioMerieux Spends $60M to Acquire Private Molecular Dx Firm

BioMerieux Spends $60M to Acquire Private Molecular Dx Firm

Sep 11, 2008
NEW YORK (GenomeWeb News) – BioMerieux today announced that is has acquired privately held molecular diagnostics firm AviaraDx for $60 million.
 
San Diego-based AviaraDx makes tests — the CancerTYPE ID and Breast Cancer IndexSM — that are used for the molecular classification of cancers and to aid oncologists in making therapeutic decisions. BioMerieux said that with the acquisition it gains validated cancer biomarkers as well as capabilities in gene expression profiling in tissues for oncology applications.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Drive Resistance

Gene drives might run into biological resistance, the Economist reports.

Dalí DNA Collected

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Synthetic-Conservation Biology Disconnect

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

This Week in Science

In Science this week: full CRISPR locus integration complex structure, and more.

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.